文献速递血栓与止血

抗PF4疾病:发病机制、诊断与治疗

Anti-PF4 disorders: Pathogenesis, diagnosis and treatment.
PubMed 文献 · Br J Haematol · 2025-07-01

血小板因子4(PF4)与带负电荷分子形成复合物,被IgG抗体靶向可导致肝素诱导的血小板减少症(HIT)和疫苗诱导的免疫性血小板减少症和血栓形成(VITT)/VITT样疾病。本综述讨论抗PF4疾病的发病机制、诊断与管理。

要点

  • HIT主要由肝素暴露触发,VITT发生于特定SARS-CoV-2疫苗接种后。
  • VITT样疾病在无肝素或SARS-CoV-2疫苗接种情况下引起血小板活化。
  • HIT和VITT/VITT样疾病的临床评估基于血栓事件、血小板计数和D-二聚体水平。

核心结论

  • 本综述讨论了抗PF4疾病的发病机制、诊断与管理。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • PF4为阳离子蛋白,自身组装为四聚体后能与带负电荷分子形成复合物。
  • IgG抗体靶向PF4复合物可导致HIT和VITT/VITT样疾病。
  • IgG/PF4免疫复合物通过IgG介导的Fcγ受体结合促进血小板、中性粒细胞和单核细胞的失控活化。
  • 腺病毒载体的六邻体蛋白可能与PF4形成复合物,从而在VITT中触发抗PF4抗体产生。
  • VITT样疾病为在无肝素或SARS-CoV-2疫苗接种情况下引起血小板活化的新型抗PF4疾病。

关键数值与推荐

  • HIT和VITT/VITT样疾病的临床评估基于血栓事件、血小板计数和D-二聚体水平。
  • 肝素/PF4诱导的血小板活化试验等实验室检测可用于区分HIT与VITT。
  • HIT和VITT的治疗方案可能因患者群体而异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet factor 4 (PF4) is a cationic protein, able to form complexes with negatively charged molecules upon its self-assembly into PF4 tetramers. The targeting of these PF4 complexes by immunoglobulin G (IgG) antibodies underlies anti-PF4 disorders such as heparin-induced thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)/VITT-like disorders. The formation of IgG/PF4 immune complexes facilitates uncontrolled activation of platelets, neutrophils and monocytes, via IgG-mediated Fcγ receptor binding. This promotes the thrombocytopenia and thrombosis characteristic of anti-PF4 disorders. HIT is predominantly triggered by heparin exposure. VITT is a recently recognised anti-PF4 disorder, which developed following specific SARS-CoV-2 vaccinations. It is thought that hexon proteins, components of adenoviral vectors, may form complexes with PF4 to trigger anti-PF4 antibody production in VITT. A novel anti-PF4 disorder has been recognised causing platelet activation without the administration of heparin or SARS-CoV-2 vaccination and referred to as 'VITT-like disorder.' Clinical evaluation of HIT and VITT/VITT-like disorders is based on thrombotic events, platelet counts and D-dimer levels. Laboratory assays such as heparin/PF4-induced platelet activation assays can be used to distinguish between HIT and VITT. Treatment plans for HIT and VITT may differ across patient groups. In this review, we discuss the pathogenesis, diagnosis and management of anti-PF4 disorders.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Preece MV, Pathak DV, Laffan M, et al. Anti-PF4 disorders: Pathogenesis, diagnosis and treatment. Br J Haematol. 2025. PMID: 40589323. doi:10.1111/bjh.20216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。